Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
Christina Wang,Glenn R. Cunningham,Adrian S. Dobs,Ali Iranmanesh,Alvin M. Matsumoto,Peter J. Snyder,Thomas Weber,Nancy Berman,Laura Hull,Ronald S. Swerdloff +9 more
Reads0
Chats0
TLDR
It is concluded that continued application of AndroGel resulted in beneficial effects similar to those with injectables and other transdermal preparations and monitoring for prostatic disease and assessment for erythrocytosis are strongly advised to reduce the risk of adverse events with T treatment of hypogonadal men.Abstract:
Transdermal testosterone (T) delivery represents an effective alternative to injectable androgens. We studied 163 hypogonadal men who applied 5, 7.5, or 10 g AndroGel (T gel) 1% CIII per day for up to 42 months. Efficacy data were presented in 123 subjects considered evaluable. Continuous AndroGel treatment normalized mean serum T and free T levels. Mean serum 5alpha-dihydrotestosterone concentrations and 5alpha-dihydrotestosterone/T ratio slightly increased, mean serum estradiol/T ratio doubled, and mean serum FSH and LH levels were suppressed by T replacement. Sexual function and mood parameters improved rapidly and were maintained throughout T treatment. Lean body mass increased (P = 0.0001) and fat mass decreased (P = 0.0001), and these changes were maintained with treatment but were not accompanied by significant increases in muscle strength. Increases in serum bone markers suggestive of increased bone formation were followed by gradual and progressive increases in bone mineral density more in the spine (P = 0.0001) than the hip (P = 0.0004). Mild local skin irritation occurred in 12 subjects, resulting in discontinuation in only one subject. Except for the anticipated increase in hematocrit and hemoglobin, there were no clinically significant changes in blood counts or biochemistry. In three subjects with elevated serum prostate-specific antigen, prostate biopsies showed cancer. We conclude that continued application of AndroGel resulted in beneficial effects similar to those with injectables and other transdermal preparations. This study was neither placebo controlled nor powered to determine the effects of T treatment on prostate cancer risk. Thus, monitoring for prostatic disease and assessment for erythrocytosis are strongly advised to reduce the risk of adverse events with T treatment of hypogonadal men.read more
Citations
More filters
Journal ArticleDOI
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.
Shalender Bhasin,Glenn R. Cunningham,Frances J. Hayes,Alvin M. Matsumoto,Peter J. Snyder,Ronald S. Swerdloff,Victor M. Montori +6 more
TL;DR: The guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men published previously in 2006 were updated by the Task Force of the Clinical Guidelines Subcommittee of The Endocrine Society.
Journal ArticleDOI
Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
Shalender Bhasin,Glenn R. Cunningham,Frances J. Hayes,Alvin M. Matsumoto,Peter J. Snyder,Ronald S. Swerdloff,Victor M. Montori +6 more
TL;DR: The Task Force recommends testosterone therapy for symptomatic men with androgen deficiency, who have low testosterone levels, to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density.
Journal ArticleDOI
Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis.
Andrea M. Isidori,Elisa Giannetta,Emanuela A. Greco,Daniele Gianfrilli,V. Bonifacio,Aldo Isidori,Andrea Lenzi,Andrea Fabbri +7 more
TL;DR: A systematic review of randomized controlled trials evaluating the effects of testosterone administration to middle‐aged and ageing men on body composition, muscle strength, bone density, markers of bone metabolism and serum lipid profile concludes that androgen treatment might be beneficial in these subjects.
Journal ArticleDOI
Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment
Ulrich Boehm,Pierre Bouloux,Mehul T. Dattani,Nicolas de Roux,Catherine Dodé,Leo Dunkel,Andrew A. Dwyer,Paolo Giacobini,J.-P. Hardelin,Anders Juul,Mohamad Maghnie,Nelly Pitteloud,Vincent Prevot,Taneli Raivio,Manuel Tena-Sempere,Richard Quinton,Jacques Young +16 more
TL;DR: A timely diagnosis and treatment to induce puberty can be beneficial for sexual, bone and metabolic health, and might help minimize some the psychological effects of CHH.
Journal ArticleDOI
Hormonal replacement in hypopituitarism in adults: An endocrine society clinical practice guideline
Maria Fleseriu,Ibrahim A. Hashim,Niki Karavitaki,Niki Karavitaki,Shlomo Melmed,M. Hassan Murad,Roberto Salvatori,Mary H. Samuels +7 more
TL;DR: Using an evidence-based approach, this guideline addresses important clinical issues regarding the evaluation and management of hypopituitarism in adults, including appropriate biochemical assessments, specific therapeutic decisions to decrease the risk of co-morbidities due to hormonal over-replacements or under-replacement, and managing hypopitsuits during pregnancy, pituitary surgery, and other types of surgeries.
References
More filters
Journal ArticleDOI
The Influence of Finasteride on the Development of Prostate Cancer
Ian M. Thompson,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Gary J. Miller,Leslie G. Ford,Michael M. Lieber,R. Duane Cespedes,JN Atkins,Scott M. Lippman,Susie M. Carlin,Anne Ryan,Connie M. Szczepanek,John Crowley,Charles A. Coltman +14 more
TL;DR: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
Journal ArticleDOI
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Eric P. Smith,Jeff Boyd,Graeme R. Frank,Hiroyuki Takahashi,Robert M. Cohen,Bonny Specker,Timothy C. Williams,Dennis B. Lubahn,Kenneth S. Korach +8 more
TL;DR: Disruption of the estrogen receptor in humans need not be lethal and is important for bone maturation and mineralization in men as well as women.
Journal ArticleDOI
Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
TL;DR: A novel mutation in the CYP19 gene in a sister and brother exhibited the cardinal features of the aromatase deficiency syndrome as recently defined and was reported on.
Journal ArticleDOI
Effect of testosterone and estradiol in a man with aromatase deficiency.
Cesare Carani,Kenan Qin,Manuela Simoni,Marco Faustini-Fustini,Stefania Serpente,Jeff Boyd,Kenneth S. Korach,Evan R. Simpson +7 more
TL;DR: The responses to androgen and estrogen in a man with a novel, homozygous inactivating mutation of cytochrome P-450 aromatase suggest a crucial role of estrogen in skeletal maturation.
Journal ArticleDOI
Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men
Christina Wang,Ronald S. Swerdloff,Ali Iranmanesh,Adrian S. Dobs,Peter J. Snyder,Glenn R. Cunningham,Alvin M. Matsumoto,Thomas Weber,Nancy Berman +8 more
TL;DR: It is concluded that T gel replacement improved sexual function and mood, increased lean mass and muscle strength (principally in the legs), and decreased fat mass in hypogonadal men with less skin irritation and discontinuation compared with the recommended dose of the permeation-enhanced T patch.